Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 8:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: After Hours Clear all
Terminated Phase 3 Interventional Results available

A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor

NCT02377466
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban IV infusion, Placebo IV infusion
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
33
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 19, 2026, 8:29 PM EDT
Active, not recruiting Phase 1 Interventional

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

NCT03016377
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
Interventions
iC9-CAR19 cells, Rimiducid, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
3 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2037
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 19, 2026, 8:29 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Thrive With Type 1 Diabetes 2026

NCT07522866
View directory record Official record
Conditions
Type1diabetes
Interventions
TranS-C Intervention Arm, Attention Control Enhanced Usual Care (EUC) Arm
Behavioral
Lead sponsor
Emory University
Other
Eligibility
31 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 19, 2026, 8:29 PM EDT
Terminated Phase 2 Interventional Results available

COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19

NCT04363437
View directory record Official record
Conditions
Coronavirus Infection
Interventions
Colchicine, Usual Care
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Sep 19, 2026, 8:29 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Easing Psychosocial Burden for Informal Caregivers

NCT03454295
View directory record Official record
Conditions
Glioblastoma
Interventions
Focus Group, Meaning-Centered Psychotherapy for Cancer Caregivers / MCP-C, Enhanced Usual Care / EUC
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
3
States / cities
Commack, New York • Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2024 · Synced Sep 19, 2026, 8:29 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

NCT02289495
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232, Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 19, 2026, 8:29 PM EDT
Completed No phase listed Observational

Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention

NCT03662295
View directory record Official record
Conditions
Migraine Disorders, Aphasia
Interventions
Language treatment
Behavioral
Lead sponsor
Quality Living, Inc.
Other
Eligibility
19 Years to 65 Years
Enrollment
1 participant
Timeline
2018 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 19, 2026, 8:29 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

NCT05609370
View directory record Official record
Conditions
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Interventions
Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar, Fluoropyrimidine (FP)
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
30
States / cities
Anchorage, Alaska • Gilbert, Arizona • Cerritos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 19, 2026, 8:29 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors

NCT00002594
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumor
Interventions
Sargramostim, cyclophosphamide, melphalan, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 25 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2007
U.S. locations
103
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 19, 2026, 8:29 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Assessment of Sodium Sulfide in Subjects With Impaired Renal Function

NCT00879645
View directory record Official record
Conditions
Renal Impairment
Interventions
Sodium Sulfide
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 19, 2026, 8:29 PM EDT
Recruiting Not applicable Interventional

Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial

NCT06802172
View directory record Official record
Conditions
Rectal Cancer Stage II, Rectal Cancer Stage III, Breast Cancer Stage I, Rectal Cancer Stage IV, Breast Cancer Stage II, Breast Cancer Stage III, Solid Tumor Cancer
Interventions
Time-restricted eating, Questionnaire Administration, Biospecimen Collection, Health coaching
Behavioral · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 19, 2026, 8:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Better Together: A Web-based Relationship Education Tool

NCT03953495
View directory record Official record
Conditions
Same-Sex Relationships
Interventions
Better Together
Behavioral
Lead sponsor
Sharon Scales Rostosky
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Sep 19, 2026, 8:29 PM EDT
Completed Not applicable Interventional

APOL1 Genetic Testing Program for Living Donors, Part 2

NCT04999436
View directory record Official record
Conditions
Chronic Kidney Diseases, Genetic Predisposition
Interventions
APOL1 Counseling Training Program
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 19, 2026, 8:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

SAY San Diego Dad Corps FIRE Program Evaluation

NCT05244421
View directory record Official record
Conditions
Fathers
Interventions
Primary Services
Other
Lead sponsor
Midwest Evaluation & Research
Other
Eligibility
18 Years and older · Male only
Enrollment
444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 19, 2026, 8:29 PM EDT
Active, not recruiting Phase 1 Interventional

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

NCT04518748
View directory record Official record
Conditions
Liver Malignancy
Interventions
Yttrium-90, Selective Internal Radiation Therapy, Stereotactic Body Radiation Therapy, PET/CT, Therasphere
Drug · Device · Radiation + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 19, 2026, 8:29 PM EDT
Completed Early Phase 1 Interventional

A Microdose Evaluation Study of ABY-029 in Primary Sarcoma

NCT03154411
View directory record Official record
Conditions
Primary Soft-tissue Sarcoma
Interventions
ABY-029
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 29, 2021 · Synced Sep 19, 2026, 8:29 PM EDT
Active, not recruiting Phase 1 Interventional

Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

NCT02637934
View directory record Official record
Conditions
Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Interventions
[18F]FluorThanatrace, PET/CT imaging sessions
Drug · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 19, 2026, 8:29 PM EDT
Recruiting Not applicable Interventional

Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors

NCT04908709
View directory record Official record
Conditions
Malignant Brain Glioma
Interventions
Magnetic Resonance Spectroscopic Imaging, Proton Therapy
Procedure · Device
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 19, 2026, 8:29 PM EDT
Completed Not applicable Interventional

Pre-Active PD: Looking At Physical Activity Behavior Change in Parkinson's Disease

NCT05308238
View directory record Official record
Conditions
Parkinson Disease
Interventions
Occupational therapy intervention group, Disease management education group
Behavioral
Lead sponsor
San Jose State University
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
San Jose, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 19, 2026, 8:29 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Refitting Satisfied INFUSE One-Day Multifocal Wearers to DAILIES TOTAL1 Multifocal Contact Lenses

NCT07638943
View directory record Official record
Conditions
Contact Lens Comfort and Successful Refitting, Presbyopia
Interventions
DAILIES TOTAL1 Multifocal (delefilcon A)
Device
Lead sponsor
Gordon Schanzlin New Vision
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 19, 2026, 8:29 PM EDT
Terminated Not applicable Interventional Results available

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

NCT01275664
View directory record Official record
Conditions
Nausea and Vomiting, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Stage II Ovarian Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Ovarian Carcinoma
Interventions
Adjuvant Therapy, Aprepitant, Carboplatin, Cisplatin, Dexamethasone, Granisetron Transdermal Patch, Management of Therapy Complications, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Hinsdale, Illinois • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Sep 19, 2026, 8:29 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults

NCT00302393
View directory record Official record
Conditions
Healthy
Interventions
OROS methylphenidate hydrochloride, methylphenidate hydrochloride
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2013 · Synced Sep 19, 2026, 8:29 PM EDT
Completed No phase listed Observational

RBC Irradiation, Anemia and Gut Injury

NCT02741648
View directory record Official record
Conditions
Anemia, Necrotizing Enterocolitis
Interventions
Near Infrared Spectroscopy, Non-invasive Image-based Anemia Assessment
Device · Other
Lead sponsor
Emory University
Other
Eligibility
1 Day to 5 Days
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 19, 2026, 8:29 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone

NCT05582707
View directory record Official record
Conditions
Intracerebral Haemorrhage, Intraventricular
Interventions
Pioglitazone 15mg
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 19, 2026, 8:29 PM EDT